Sutent Evropska unija - latvijščina - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiski līdzekļi - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Sunitinib Teva 12,5 mg cietās kapsulas Latvija - latvijščina - Zāļu valsts aģentūra

sunitinib teva 12,5 mg cietās kapsulas

teva b.v., netherlands - sunitinibs - kapsula, cietā - 12,5 mg

Sunitinib Teva 50 mg cietās kapsulas Latvija - latvijščina - Zāļu valsts aģentūra

sunitinib teva 50 mg cietās kapsulas

teva b.v., netherlands - sunitinibs - kapsula, cietā - 50 mg

Sunitinib Mylan 12,5 mg cietās kapsulas Latvija - latvijščina - Zāļu valsts aģentūra

sunitinib mylan 12,5 mg cietās kapsulas

mylan ireland limited, ireland - sunitinibs - kapsula, cietā - 12,5 mg

Sunitinib Mylan 50 mg cietās kapsulas Latvija - latvijščina - Zāļu valsts aģentūra

sunitinib mylan 50 mg cietās kapsulas

mylan ireland limited, ireland - sunitinibs - kapsula, cietā - 50 mg